AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

U.S. Markets closed

AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,609.00+8.50 (+0.18%)
At close: 5:11PM GMT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4,600.50
Open4,601.50
Bid4,560.00 x 6100
Ask4,630.00 x 13000
Day's Range4,568.50 - 4,675.17
52 Week Range3,680.00 - 5,505.00
Volume2,029,277
Avg. Volume3,000,438
Market Cap58.32B
Beta0.58
PE Ratio (TTM)16.70
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (4.82%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
    Zacks2 days ago

    Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

    Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

  • Benzinga4 days ago

    Analyst: Buy AstraZeneca On The Turnaround Story

    Following AstraZeneca plc (ADR) (NYSE: AZN )’s strong start to 2017, including a positive data report for breast cancer treatment Lynparza, investors await a barrage of news highlighting significant findings ...

  • American City Business Journals5 days ago

    $250M deal: AstraZeneca sells rights to cancer therapy

    AstraZeneca entered into an agreement to sell the rights to a cancer drug in the United States and Canada to TerSera Therapeutics for an upfront payment of $250. The deal could also net AstraZeneca up to $70 million in sales-related income if revenue milestones are met, along with recurring quarterly sales-based payments that are set at a mid-teen percent of product sales. TerSera Therapeutics, which has offices in Iowa and Illinois, acquired the rights to Zoladex, an injectable drug used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.